iTeos Therapeutics, Inc.
ITOS
$7.77
$0.273.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.00% | -2.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.47% | -0.30% | |||
| Operating Income | 18.47% | 0.30% | |||
| Income Before Tax | 7.82% | 15.67% | |||
| Income Tax Expenses | -85.04% | 227.91% | |||
| Earnings from Continuing Operations | 20.82% | 3.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.82% | 3.63% | |||
| EBIT | 18.47% | 0.30% | |||
| EBITDA | 18.59% | 0.34% | |||
| EPS Basic | 20.92% | 3.73% | |||
| Normalized Basic EPS | 7.94% | 15.77% | |||
| EPS Diluted | 21.00% | 3.63% | |||
| Normalized Diluted EPS | 7.94% | 15.77% | |||
| Average Basic Shares Outstanding | 0.14% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||